YOKNEAM ILLIT, Israel– ForSight Robotics has raised $125 million in a Series B funding round to accelerate the development and clinical rollout of its ORYOM™ robotic surgery platform, the first designed specifically for ophthalmic procedures. The investment comes amid growing global demand for cataract surgeries and a shrinking pool of available surgeons, positioning the company to address one of the most pressing challenges in eye care today.
The round was led by Eclipse, with participation from a strategic investor, Dr. Fred Moll, the Adani Group, Reiya Ventures, and existing backers. The latest capital infusion brings ForSight Robotics’ total funding to $195 million and will support the launch of first-in-human clinical trials for robotic cataract surgery later this year.
“With ophthalmology facing the kind of transformation general surgery underwent with the rise of robotic systems like da Vinci, we see an enormous opportunity to redefine how eye surgery is performed,” said Dr. Joseph Nathan, co-founder, president, and chief medical officer of ForSight Robotics. “The ORYOM platform is built specifically for the unique precision demands of ophthalmology and aims to expand access to care worldwide.”
The global vision crisis continues to grow, with over one billion people suffering from preventable vision impairment or blindness. Cataract remains the leading cause, affecting more than 600 million people worldwide. Yet only a fraction of those in need—about 30 million—receive surgical treatment annually. In the United States, four million cataract procedures are performed each year, far below the actual need. Simultaneously, the number of trained ophthalmologists is projected to decline by 12% globally by 2035, while patient demand is expected to rise by 24%.
Designed to address this gap, ForSight’s ORYOM platform integrates artificial intelligence, advanced computer vision, and micromechanical robotics to enable high-precision eye surgery. The system allows for navigation across both anterior and posterior segments of the eye, laying the groundwork for future applications in glaucoma and retinal procedures. The company has already demonstrated success with animal eye models and is preparing for human trials in the coming months.
“ForSight Robotics is pioneering a much-needed transformation in surgical robotics, one that could redefine global access to high-quality ophthalmic care,” said Seth Winterroth, partner at Eclipse. “They’re targeting an immense unmet need with a breakthrough technology.”
The company has also achieved several key milestones, including ISO 13485:2016 certification and significant team expansion. ForSight now employs more than 110 people and has assembled an advisory board of leading voices in surgical robotics and ophthalmology. Among them is Dr. Fred Moll, the founder of Intuitive Surgical, who recently joined ForSight’s board of directors.
As the company advances toward commercialization, its leadership sees the ORYOM platform as a critical tool in resolving the surgeon shortage and ensuring broader access to sight-saving procedures. By leveraging robotic precision, scalability, and surgeon support, ForSight aims to make high-quality eye surgery accessible to more patients around the world.
